196 related articles for article (PubMed ID: 34929598)
21. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
[TBL] [Abstract][Full Text] [Related]
22. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
23. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
[TBL] [Abstract][Full Text] [Related]
24. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers.
Giovanella L; Crippa S; Cariani L
Int J Biol Markers; 2008; 23(2):129-31. PubMed ID: 18629788
[TBL] [Abstract][Full Text] [Related]
25. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
[TBL] [Abstract][Full Text] [Related]
26. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
27. Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment.
Fugazzola L; Di Stefano M; Censi S; Repaci A; Colombo C; Grimaldi F; Magri F; Pagotto U; Iacobone M; Persani L; Mian C
J Endocrinol Invest; 2021 Mar; 44(3):587-597. PubMed ID: 32656666
[TBL] [Abstract][Full Text] [Related]
28. Negative predictive value of procalcitonin in medullary thyroid carcinoma.
Lim SK; Guéchot J; Vaubourdolle M
Ann Biol Clin (Paris); 2016; 74(2):213-8. PubMed ID: 26806393
[TBL] [Abstract][Full Text] [Related]
29. Other markers of medullary thyroid cancer, not only calcitonin.
Censi S; Manso J; Mian C
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
[TBL] [Abstract][Full Text] [Related]
30. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
[TBL] [Abstract][Full Text] [Related]
31. Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?
Niederle MB; Scheuba C; Riss P; Selberherr A; Koperek O; Niederle B
Thyroid; 2020 Jul; 30(7):974-984. PubMed ID: 32056502
[No Abstract] [Full Text] [Related]
32. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract][Full Text] [Related]
33. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
Miao Q; Lv X; Luo L; Zhang J; Cai B
Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
[TBL] [Abstract][Full Text] [Related]
34. Serum miR-375 for Diagnostic and Prognostic Purposes in Medullary Thyroid Carcinoma.
Censi S; Bertazza L; Piva I; Manso J; Benna C; Iacobone M; Mondin A; Plebani M; Faggian D; Galuppini F; Pennelli G; Barollo S; Mian C
Front Endocrinol (Lausanne); 2021; 12():647369. PubMed ID: 33854485
[TBL] [Abstract][Full Text] [Related]
35. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review.
Karagiannis AK; Girio-Fragkoulakis C; Nakouti T
Anticancer Res; 2016 Aug; 36(8):3803-10. PubMed ID: 27466480
[TBL] [Abstract][Full Text] [Related]
36. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
[TBL] [Abstract][Full Text] [Related]
38. Thresholds of Basal- and Calcium-Stimulated Calcitonin for Diagnosis of Thyroid Malignancy.
Băetu M; Olariu CA; Stancu C; Caragheorgheopol A; Ioachim D; Moldoveanu G; Corneci C; Badiu C
Horm Metab Res; 2021 Dec; 53(12):779-786. PubMed ID: 34687025
[TBL] [Abstract][Full Text] [Related]
39. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer.
Chiacchiarini M; Trocchianesi S; Besharat ZM; Po A; Ferretti E
Pharmacol Ther; 2021 Mar; 219():107708. PubMed ID: 33091426
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
